Recent research has uncovered a significant link between copper levels in the brain and demyelination, the process of myelin degradation characteristic of multiple sclerosis (MS). In a laboratory model, scientists observed that demyelination in the corpus callosum—a major white matter tract connecting the brain’s hemispheres—was closely associated with a notable reduction in soluble copper, while insoluble copper remained unaffected.
To explore potential treatments, the researchers administered a copper compound capable of crossing the blood-brain barrier. This intervention increased soluble copper levels in the brain and significantly reduced demyelination in the corpus callosum. These findings suggest that enhancing soluble copper in the brain may help preserve myelin and offer a new avenue for therapeutic strategies in MS.
While further research is necessary to fully understand the role of copper in MS, this study provides promising insights into potential treatments aimed at mitigating demyelination and improving outcomes for individuals living with the condition.